Ken Cacciatore
Stock Analyst at TD Cowen
(0.33)
# 4,322
Out of 5,124 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $30.20 | +65.56% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $7.40 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $15.69 | +27.47% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $16.80 | +108.33% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.21 | +1,087.28% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.39 | +827.64% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $9.93 | +353.17% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $13.50 | +3,307.41% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $30.20
Upside: +65.56%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.40
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $15.69
Upside: +27.47%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $16.80
Upside: +108.33%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.21
Upside: +1,087.28%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.39
Upside: +827.64%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $9.93
Upside: +353.17%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $13.50
Upside: +3,307.41%